Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Blood Sugar Archives
Print | Email | Share | Comments (0)

Appetite Suppressant

Nov 1, 1995

Five percent of people with type 2 diabetes develop secondary failure to sulfonylureas every year (secondary failure describes the condition wherein a drug that has been effective in controlling blood sugars stops functioning for a particular individual).

Such failure is usually caused by poor adherence to diet. Although the ideal treatment is weight control through better eating habits, D. Kumar of Los Angeles says few patients follow such advice.

Kumar led a study in which it was found that the appetite suppressant dexfenfluramine, given in conjunction with sulfonylureas, is an effective method for preventing failure. Most patients who fail on sulfonylureas are treated with insulin. This treatment often leads to weight gain and chronic hyperinsulinemia. Dexfenfluramine promotes weight loss and appears to provide users with lower basal blood insulin levels than insulin-treated people.

According to Kumar, "These data suggest that the appetite suppressant dexfenfluramine is a preferred treatment for the secondary failure to sulfonylureas".

Dexfenfluramine will be sold in this country under the trade name "Redux", and is being developed by Interneuron of Boston, Mass. The drug is currently up for approval by the FDA, and is being reviewed in advisory committee meetings, which are open to the public. The meetings begin November 16th in Wash., D.C.

This research was presented at the 22nd Annual Meeting and Educational Program of the AADE in Boston, August 1995.


Categories: Blood Sugar, Diabetes, General, Insulin, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Nov 1, 1995

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.